Der gemeinsame Zimtmetaboliten zeigt das Potenzial für die Behandlung von Alzheimer, indem Amyloid im Blut reduziert wird

From the article: A new study suggests that an oral medication, sodium benzoate, may reduce the levels of disease-related proteins in the blood of patients with mild Alzheimer’s disease. The research also indicates that patients who had higher initial levels of a specific protein, called amyloid-beta 1–42, experienced greater cognitive benefits from the treatment. These findings, [published](https://www.nature.com/articles/s41398-025-03492-3) in the journal Translational Psychiatry, point toward a potentially safe and convenient therapeutic option for individuals with Alzheimer’s disease.

Alzheimer’s disease is a progressive brain disorder that gradually diminishes memory and other important mental functions. For decades, a leading theory has suggested that the buildup of proteins called amyloid-beta peptides in the brain is a primary cause of the nerve cell damage and cognitive decline seen in the disease. This idea has gained support with the recent approval of new treatments that directly target and remove these amyloid-beta proteins.

These therapies, which are administered through intravenous infusions, have shown an ability to slow cognitive decline. However, they can be associated with side effects, including brain swelling or bleeding, and they present logistical challenges for patients and healthcare systems due to their high cost and the need for regular hospital visits for infusions and monitoring.

This situation has prompted a search for safer and more accessible treatments that can also address the amyloid-beta buildup. One candidate is sodium benzoate, a compound that is a metabolite of cinnamon and is widely used as a food preservative. It is also approved as a treatment for certain metabolic disorders.

Im going to leave this to the Alzheimer’s researchers to assess, because I’ve grown skeptical of our collective understanding of the causal relationship between amyloid and Alzheimer’s.